Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 1 · 16.7%High 0 · 0%

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.77 [0.39, 1.53]
4 studies · 1055 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Minor bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.83 [0.57, 1.23]
4 studies · 1055 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Thrombocytopenia · patients with active cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Health related quality of life · patients with active cancer with venous thromboembolism

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 8485 participants
Moderate

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.94 [0.72, 1.23]
4 studies · 1060 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.63 [0.34, 1.15]
4 studies · 1050 participants
Low